Home›Ertugliflozin And Sitagliptin

Ertugliflozin And Sitagliptin

Also known as: Steglujan

Route: Oral

Check Ertugliflozin And Sitagliptin Interactions →

2 interactions on record

Ertugliflozin And Sitagliptin has 2 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Insulin Human, Lithium. Patients taking Ertugliflozin And Sitagliptin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 2
Major: 1
Moderate: 1

Major (1)

Ertugliflozin And Sitagliptin + Insulin Human— Concomitant use increases risk of hypoglycemia. Lower doses of insulin may be required when used with STEGLUJAN.

Moderate (1)

Ertugliflozin And Sitagliptin + Lithium— SGLT2 inhibitor component may decrease serum lithium concentrations. Monitor serum lithium concentration more frequently…

Ertugliflozin And Sitagliptin + Insulin Human⚠️Major

Concomitant use increases risk of hypoglycemia. Lower doses of insulin may be required when used with STEGLUJAN.

Ertugliflozin And Sitagliptin + Lithium🟡Moderate

SGLT2 inhibitor component may decrease serum lithium concentrations. Monitor serum lithium concentration more frequently during initiation and dosage changes.

Contraindications

4 CONTRAINDICATIONS STEGLUJAN is contraindicated in patients with: Severe renal impairment (eGFR less than 30 mL/min/1.73 m 2 ), end-stage renal disease (ESRD), or on dialysis [see Warnings and Precautions (5.4) and Use in Specific Populations (8.6) ] . Hypersensitivity to sitagliptin, ertugliflozin, or any excipient, in STEGLUJAN. Reactions such as anaphylaxis or angioedema have occurred [see Warnings and Precautions (5.11) and Adverse Reactions (6.2) ]. Severe renal impairment (eGFR less than 30 mL/min/1.73 m 2 ), end-stage renal disease, or dialysis. ( 4 ) Hypersensitivity to sitagliptin, ertugliflozin, or any excipient in STEGLUJAN. ( 4 , 5.11 , 6.2 )

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary Based on animal data showing adverse renal effects, from ertugliflozin, STEGLUJAN is not recommended during the second and third trimesters of pregnancy. The limited available data with ertugliflozin and sitagliptin use during pregnancy are not sufficient to determine a drug associated risk of adverse developmental outcomes. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations ) . In animal studies, adverse renal changes were observed in rats when ertugliflozin was administered during a period of renal development corresponding to the late second and third trimesters of human pregnancy. Doses approximately 13 times the maximum clinical dose caused renal pelvic and tubule dilatations and renal mineralization that were not fully reversible. There was no evidence of fetal harm in rats or rabbits at exposures of ertugliflozin approximately 300 times higher than the maximal clinical dose of 15 mg/day when administered during organogenesis (see Data ) . In rats and rabbits, sitagliptin doses of 250 and 125 mg/kg, respectively (approximately 30 and 20 times the human exposure at the maximum recommended human dose) did not adversely affect development outcomes of either species. The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20-25% in women with HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.